Beijing Minhai Biological Technology Co., Ltd.

DUBLIN, March 7, 2024 /PRNewswire/ -- The "Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering. Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. Fully revised and updated, the report provides details of co-promotion and co-marketing deals from 2016 to 2024, the report provides access to co-promotion and co-marketing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of co-promotion and co-marketing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of co-promotion and co-marketing deals. Chapter 4 provides a review of the leading co-promotion and co-marketing deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a comprehensive listing of the top 25 most active co-promotion and co-marketing dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. Chapter 6 provides a comprehensive and detailed review of co-promotion and co-marketing deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the co-promotion and co-marketing deal. The deal directory includes a comprehensive listing of all co-promotion and co-marketing deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document. The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing alliances. Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits: Understand deal trends since 2016 Browse co-promotion and co-marketing deals Benchmark analysis - identify market value of transactions Financials terms Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology includes: Trends in co-promotion and co-marketing dealmaking in the biopharma industry Overview of co-promotion and co-marketing deal structure Directory of co-promotion and co-marketing deal records covering pharmaceutical and biotechnology The leading co-promotion and co-marketing deals by value Most active co-promotion and co-marketing dealmakers The leading co-promotion and co-marketing partnering resources Analyzing contract agreements allows due diligence of: What are the rights granted or optioned? What rights are granted by the agreement? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are intellectual property rights handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in co-promotion and co-marketing dealmaking 2.1. Introduction 2.2. Definition of co-promotion and co-marketing deals 2.3. Trends in co-promotion and co-marketing deals since 2016 2.3.1. Co-promotion and co-marketing dealmaking by year, 2016-2024 2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2016-2024 2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2016-2024 2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2016-2024 2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2016-2024 2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2016-2024 2.4. Reasons for entering into co-promotion and co-marketing partnering deals 2.5. The future of co-promotion and co-marketing deals Chapter 3 - Overview of co-promotion and co-marketing deal structure 3.1. Introduction 3.2. Co-promotion and co-marketing agreement structure Chapter 4 - Leading co-promotion and co-marketing deals 4.1. Introduction 4.2. Top co-promotion and co-marketing deals by value Chapter 5 - Top 25 most active co-promotion and co-marketing dealmakers 5.1. Introduction 5.2. Top 25 most active co-promotion and co-marketing dealmakers Chapter 6 - Co-promotion and co-marketing deals including contracts directory 6.1. Introduction 6.2. Co-promotion and co-marketing deals with contracts 2016-2024 Deal directory Deal directory - Co-promotion and co-marketing dealmaking by companies A-Z Deal directory - Co-promotion and co-marketing dealmaking by therapy area Deal directory - Co-promotion and co-marketing dealmaking by technology type Some of the companies featured 3D Medicines 4D Molecular Therapeutics Abbvie AbCellera Biologics ALK-Abello Allegis Pharmaceuticals Allergan Bausch & Lomb Baxalta Bayer Beam Therapeutics BeiGene Beijing Minhai Biotechnology Belharra Therapeutics Belintra Berlin Chemie BioAge Labs Biogen Biognosys Biological Industries BioNano Genomics BioNTech Cipher Pharmaceuticals Concordia Pharmaceuticals CRISPR Therapeutics CrossLink Bioscience CSL Dova Pharmaceuticals Dovetail Genomics DualityBio Eagle Genomics Eagle Pharmaceuticals EA Pharma Eli Lilly Empatica Enterome Bioscience Epizyme Eton Pharmaceuticals Exact Sciences Fabric Genomics Gilead Sciences Glenmark Pharmaceuticals Goldfinch Bio GSK GT Research H3 Biomedicine Halyard Health Hanmi Pharmaceutical Harbin Pharmaceutical Group HD Biosciences Iconic Therapeutics Idorsia IGM Biosciences Illumina Immatics Biotechnologies Immunicon ImmunityBio Ionis Pharmaceuticals Ironwood Pharmaceuticals iTeos Therapeutics Janssen Biotech Janssen Pharmaceuticals Jiangsu Alphamab Konica Minolta Kowa Pharmaceuticals America KSQ Therapeutics Kyorin Pharmaceutical Kyowa Hakko Kirin Kyverna Therapeutics Luqa Pharmaceuticals Luxcel Biosciences Lygos Macrogenics Manchester BIOGEL MannKind Biopharmaceuticals Medicines360 MedImmune Medovate MEI Pharma Menarini Merck and Co Merck KGaA Mersana Therapeutics Mesoblast Metagenomi Metavant Microsoft Nkarta Therapeutics Novartis Novo Nordisk nRichDX Numab Otonomy Otsuka Oxford BioMedica Pacira Biosciences Paragon Bioservices Pfizer Phil Prothena Provention Bio PSI (Population Services International) Purdue Pharma Pure Pharmaceuticals QED Therapeutics Qiagen Quanta Radius Health Rainbow Scientific Rakuten Medical Recludix Pharma RedHill Biopharma RefleXion Medical Regeneron Pharmaceuticals Regenxbio Relay Therapeutics Repare Therapeutics Resonant Specific Technologies Revolution Medicines Rigel Pharmaceuticals Roche Sanofi Seren Pharmaceuticals Seres Therapeutics Shimadzu Shionogi Silicon Biosystems Simcere Pharmaceuticals Sirtex Medical SK Biopharmaceuticals Solid Biosciences Sonoma BioTherapeutics Sosei SparingVision Stealth BioTherapeutics Stoke Therapeutics StrideBio Tango Therapeutics Teijin Telix Pharmaceuticals Terumo Blood and Cell Technologies Tetraphase Pharmaceuticals Teva Pharmaceutical Industries Theravance Thermo Fisher Scientific Tilak Healthcare Tilray Titan Pharmaceuticals Tolmar Urovant Sciences US WorldMeds Verity Pharmaceuticals Vertex Pharmaceuticals Vertice Pharma Vifor Pharma Voyager Therapeutics WAVE Life Sciences Xellia Pharmaceuticals Xencor ZAI Laboratory Zymeworks For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

DUBLIN--( BUSINESS WIRE )--The "Hepatitis B Vaccines: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Hepatitis B Vaccines Market to Reach $3.4 Billion by 2027 In the changed post COVID-19 business landscape, the global market for Hepatitis B Vaccines estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at a CAGR of 3.9% over the analysis period 2020-2027. Combination Vaccines, one of the segments analyzed in the report, is projected to record 4.4% CAGR and reach US$2.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Mono Vaccines segment is readjusted to a revised 3.1% CAGR for the next 7-year period. The U.S. Market is Estimated at $715.6 Million, While China is Forecast to Grow at 6.5% CAGR The Hepatitis B Vaccines market in the U.S. is estimated at US$715.6 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$668.6 Million by the year 2027 trailing a CAGR of 6.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 3.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR. Select Competitors (Total 14 Featured) - Beijing Minhai Biotechnology Co., Ltd. Bharat Biotech International Ltd. Binnopharm Group LLC Biokangtai CSL Ltd. Dynavax Technologies Corporation Emergent BioSolutions, Inc. GlaxoSmithKline PLC Hualan Biological Engineering Co., Ltd. Merck & Co., Inc. What's New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to digital archives and Research Platform Complimentary updates for one year Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights Hepatitis B Vaccines - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION Companies Mentioned Beijing Minhai Biotechnology Co., Ltd. Bharat Biotech International Ltd. Binnopharm Group LLC Biokangtai CSL Ltd. Dynavax Technologies Corporation Emergent BioSolutions, Inc. GlaxoSmithKline PLC Hualan Biological Engineering Co., Ltd. Merck & Co., Inc. For more information about this report visit https://www.researchandmarkets.com/r/oixc6p